Is Allopurinol Really Bad for Your Heart?

Allopurinol does not appear to be bad for your heart. Decades of research, including large randomized trials and observational studies involving tens of thousands of patients, consistently show that the drug does not increase cardiovascular risk. Some evidence suggests it may even be mildly protective, particularly at higher doses and with long-term use. The concern tends to arise because allopurinol is prescribed to people who already have elevated uric acid, a condition linked to greater cardiovascular risk on its own, and untangling the drug’s effects from the underlying disease has taken researchers years of careful work.

Why the Question Keeps Coming Up

Allopurinol is best known as a gout medication, but the people who take it often have a cluster of other health problems. Elevated uric acid levels are tied to increased cardiovascular risk, and research across multiple populations confirms that hyperuricemia is associated with cardiac, kidney, and vascular damage.¹ When someone on allopurinol has a heart attack, it is natural to wonder whether the drug played a role. But the baseline cardiovascular risk in gout patients is already elevated before any medication enters the picture.² Sorting cause from coincidence has been the central challenge in evaluating allopurinol’s cardiovascular safety.

What Allopurinol Does Beyond Lowering Uric Acid

Allopurinol works by blocking an enzyme called xanthine oxidase, which is one of the major sources of oxidative stress in blood vessels. By shutting down that enzyme, allopurinol reduces not only uric acid production but also the generation of harmful reactive oxygen molecules in the vascular system. Smaller studies have shown that this translates to improved blood vessel function and reduced oxygen demand on the heart muscle.³ This dual action is why researchers have long suspected allopurinol might actually help the heart, not harm it.

The Two Landmark Trials Comparing Allopurinol and Febuxostat

Much of the public anxiety about gout drugs and heart risk traces back to the CARES trial, a large study that compared allopurinol head-to-head with febuxostat, the other major urate-lowering drug. The headline finding was reassuring for allopurinol: there was no significant difference between the two drugs in the primary composite of major cardiovascular events. Cardiovascular events occurred at roughly the same rate in both groups, at about 10-11%.⁴ The alarm bells rang for febuxostat, not allopurinol: febuxostat was linked to a higher rate of cardiac death and death from any cause.⁵

The FAST trial, conducted in Europe and published in The Lancet, went further. It followed over 6,000 gout patients for a longer period and found that febuxostat was not inferior to allopurinol for the primary cardiovascular endpoint. If anything, the on-treatment analysis slightly favored febuxostat, with fewer cardiovascular events per patient-year. Deaths were somewhat more common in the allopurinol group in this trial, though the difference was modest.⁶ Taken together, the two trials make it clear that allopurinol does not carry an unusual cardiac danger. Both drugs performed similarly on the main cardiovascular outcomes, and neither raised red flags for heart attacks or strokes compared to the other.

The ALL-HEART Trial and the Limits of Protection

While allopurinol appears safe, researchers also hoped it might actively prevent heart disease in people who already had coronary artery disease. The ALL-HEART trial tested that idea by giving allopurinol to patients with established ischemic heart disease who did not necessarily have gout. The results were sobering: allopurinol did not reduce major cardiovascular events compared to usual care.⁷ Previous smaller studies had been more encouraging, and observational data had pointed toward benefit, which is why the negative result surprised many cardiologists. The takeaway is that allopurinol is safe in this population but should not be prescribed specifically to prevent heart attacks in people without gout.

Where Allopurinol Does Seem to Help the Heart

Even though the big prevention trial came up empty, allopurinol has shown real cardiovascular benefits in specific clinical settings. The most striking is in chronic stable angina. A randomized crossover trial using high-dose allopurinol (600 mg daily) found that patients could exercise for roughly a minute longer before experiencing chest pain, and about 40 seconds longer before showing signs of restricted blood flow to the heart on their electrocardiogram.⁸ That may not sound dramatic, but it is comparable to the improvement seen with some established anti-angina medications, which caught the cardiology community’s attention.

Allopurinol also appears to lower blood pressure modestly. A meta-analysis of randomized trials found that it reduced systolic blood pressure by about 3 mm Hg and diastolic blood pressure by about 1-2 mm Hg on average.⁹ In older adults with high blood pressure, the effect was similar, with a modest but consistent drop associated with allopurinol use.¹⁰ The most impressive blood pressure results came from a trial in adolescents with newly diagnosed high blood pressure, where allopurinol reduced systolic pressure by about 7 mm Hg compared to about 2 mm Hg with placebo, and two-thirds of the participants reached normal blood pressure during the treatment phase.¹¹ These effects are too small to replace dedicated blood pressure medication, but they are a cardiovascular benefit rather than a risk.

Heart Failure Is the Exception

One area where allopurinol has not lived up to its promise is heart failure. Despite the theoretical reason to think reducing oxidative stress would help a struggling heart, clinical trials have been consistently disappointing. The EXACT-HF study tested allopurinol in patients with heart failure and high uric acid levels and found no improvement in clinical status, exercise capacity, quality of life, or heart function at 24 weeks.¹² A separate trial found that while allopurinol reduced a blood marker associated with poor heart failure prognosis (BNP), it did not actually improve how far patients could walk or how well they could exercise.¹³ Allopurinol is not harmful in heart failure patients, but it should not be expected to improve the condition itself.

Dose Matters More Than Most People Realize

One consistent finding across studies is that higher doses of allopurinol tend to be associated with better cardiovascular outcomes. An observational study found that patients taking at least 300 mg daily had roughly 30% fewer cardiovascular events than those on 100 mg daily.¹⁴ This makes intuitive sense: higher doses suppress more xanthine oxidase activity and produce a greater reduction in oxidative stress. The angina trial that showed benefit used 600 mg daily, far above the 100-200 mg that many gout patients are prescribed. Interestingly, one study found that the achieved uric acid level itself did not predict cardiovascular events among allopurinol users, suggesting the benefit comes from the enzyme inhibition rather than from how low uric acid goes.¹⁵ In practice, many patients are left on low doses indefinitely, which may mean they miss out on potential cardiovascular benefit.

The Risky Window When You First Start

If there is a period when allopurinol might be associated with increased cardiovascular risk, it is the first few months after starting the drug. A Swedish population study found that people who had just begun allopurinol had roughly 70% higher odds of a first-ever acute coronary event compared to long-term users.¹⁶ The researchers attributed this not to the drug itself but to the fact that people starting allopurinol are often in a period of active gout flares and higher systemic inflammation, both of which are cardiovascular stressors. This is a form of confounding by indication: the sickest patients are the ones being prescribed the drug for the first time, so their outcomes look worse than those of stable, long-term users.

A related finding comes from an analysis of the CARES trial data, which showed that the rate of major cardiovascular events more than doubled after patients stopped taking their study medication compared to while they were taking it.¹⁷ Stopping allopurinol causes uric acid to rebound, which may trigger gout flares and inflammation. This pattern reinforces the idea that consistent, long-term use is safer than starting and stopping.

Long-Term Use in Older Adults

Because gout disproportionately affects older adults, the safety of allopurinol in this age group deserves particular attention. A large study using U.S. Medicare data covering nearly 100,000 patients aged 65 and older found no difference in the risk of heart attack, stroke, heart failure, or death between those starting allopurinol and those starting febuxostat.¹⁸ A separate Medicare study found that allopurinol use was associated with a roughly 15% lower risk of heart attack, and the protection increased with duration: patients who used allopurinol for more than two years had about 30% lower risk compared to non-users.¹⁹

Dangerous heart rhythm problems are another concern in older people, and here too allopurinol looked favorable. A study of Medicare patients found that allopurinol use was associated with about an 18% lower risk of ventricular arrhythmias, with longer use durations showing progressively greater reductions.²⁰ These are observational findings, so they cannot prove causation, but the consistent dose-response pattern is encouraging.

The Kidney Connection

Many gout patients also have chronic kidney disease, and the relationship between allopurinol, kidney function, and heart risk is worth understanding. One randomized trial in patients with chronic kidney disease found that allopurinol slowed kidney decline and also dramatically reduced cardiovascular events compared to standard treatment.²¹ However, a larger and more rigorous trial found that allopurinol did not slow the progression of kidney disease, and the rate of serious side effects was similar between the drug and placebo groups.²² The kidney story echoes the broader cardiovascular narrative: early, smaller studies often showed benefits that larger, more definitive trials did not fully replicate. For patients with both gout and kidney problems, allopurinol remains safe to use with appropriate dose adjustment, but expectations for kidney or heart protection should be tempered.

Sex Differences in Outcomes

Most cardiovascular research on allopurinol has included a majority of men, reflecting gout’s demographics. But one large study specifically examined sex differences in heart failure risk among gout patients taking either febuxostat or allopurinol. The findings showed that febuxostat users had a higher risk of heart failure hospitalization than allopurinol users regardless of sex. Women with gout on febuxostat had a higher risk of heart failure hospitalization than men, though both sexes fared better on allopurinol than on febuxostat.²³ This is one of the few areas where allopurinol appears to have an advantage over the alternative, rather than just being equivalent.

Why Observational Studies and Trials Keep Disagreeing

A persistent frustration in this field is that observational studies tend to show cardiovascular benefit from allopurinol while randomized trials show neutrality. The observational data from Medicare databases, gout registries, and large health records repeatedly link allopurinol use to fewer heart attacks, strokes, and deaths. But when researchers test this in controlled trials where patients are randomly assigned to allopurinol or placebo, the benefits largely evaporate.

This gap has a few explanations. Observational studies struggle to fully account for the “healthy user” effect: patients who take their medication consistently tend to be healthier in ways that are difficult to measure. They may exercise more, eat better, or manage their other conditions more carefully. When they have fewer heart attacks, some of that advantage comes from who they are, not from the allopurinol itself. There is also the dose issue mentioned earlier: patients in observational studies on higher doses may genuinely be getting cardiovascular benefit from stronger xanthine oxidase inhibition, but trials that use standard doses wash out that signal. Neither type of study is wrong, but they are answering slightly different questions, and the truth probably sits somewhere between their findings.

Adherence and What Happens When You Stop

One of the more practical findings for anyone taking allopurinol is that sticking with the medication matters. A nested case-control study found that shorter durations of allopurinol use were associated with higher cardiovascular risk compared to longer use.²⁴ The pattern makes sense: intermittent use leads to uric acid swings and recurrent inflammation, both of which are hard on blood vessels. If you and your doctor decide allopurinol is appropriate, the evidence suggests that taking it consistently is safer than cycling on and off.

The data on what happens after discontinuation, as noted in the CARES analysis, reinforce this point. Cardiovascular event rates roughly doubled in the period after patients stopped their urate-lowering therapy.¹⁷ Abrupt discontinuation appears to be a riskier choice than continuing treatment, and if stopping is necessary for another medical reason, discussing a tapering plan with your prescriber is worth the conversation.

Gout Patients Who Also Have Diabetes

Gout and type 2 diabetes frequently overlap, and people living with both conditions might have particular reason to worry about adding another medication. An observational study in patients with both gout and diabetes found that current allopurinol users had about a third lower risk of stroke or heart attack compared to people who had previously used the drug and stopped.²⁵ This is observational evidence, with all the caveats that come with it, but it suggests that in this high-risk population allopurinol is at worst neutral and possibly beneficial. Importantly, there was no signal of harm.